FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer

2007 ◽  
Vol 30 (4) ◽  
pp. 377-388 ◽  
Author(s):  
Marcelo Mamede ◽  
Paula Abreu-e-Lima ◽  
Maria Raquel Oliva ◽  
V??nia Nos?? ◽  
Harvey Mamon ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Tumor Segmentation ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Alberto Zaniboni ◽  
Giordano Savelli ◽  
Claudio Pizzocaro ◽  
Pietro Basile ◽  
Valentina Massetti
Keyword(s):  
Liver Metastases ◽  
Fdg Pet ◽  
Therapy Response ◽  
Progression Free Survival ◽  
Free Survival ◽  
Positron Emission ◽  
Response To Chemotherapy ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Ct And Mri

The aim of the present paper is to review the scientific literature concerning the usefulness of18F-FDG PET/CT in the evaluation of response to chemotherapy in patients affected by liver metastases from colorectal cancer.Material and Methods. Studies were identified by searching PubMed electronic databases. Both prospective and retrospective studies were included. Information regarding the figure of merit of PET for the evaluation of therapy response was extracted and analyzed.Results. Existing data suggests that18F-FDG PET/CT may have an outstanding role in evaluating the response. The sensitivity of PET in detecting therapy response seems to be greater than conventional imaging (CT and MRI). PET/CT response is strictly related to better overall survival and progression-free survival.Conclusions. PET/CT is more than a promising technique to assess the response to chemotherapy in colorectal and liver metastases. However, to be fully validated, this examination needs further studies by recruiting more patients.

FDG-PET/CT is Predictive of Progression-free Survival in Anal Cancer

2009 ◽  
Vol 75 (3) ◽  
pp. S258-S259
Author(s):  
W.W. Lien ◽  
A.R. Rao ◽  
J.S. Kaptein ◽  
M.A. Tome
Keyword(s):  
Anal Cancer ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival

2021 ◽  
Vol 20 ◽  
pp. 153303382110564
Author(s):  
Na Dai ◽  
Hang Liu ◽  
Shengming Deng ◽  
Shibiao Sang ◽  
Yiwei Wu
Keyword(s):  
Prognostic Factor ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Lymphoblastic Lymphoma ◽  
Emission Tomography ◽  
Free Survival ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after allogeneic stem cell transplantation (allo-SCT) in lymphoblastic lymphoma (LBL) patients using Deauville Scores (DS). Materials and Methods: A total of 63 LBL patients who benefited from 18F-FDG PET-CT after allo-SCT in our institution between April 2010 and August 2020 were enrolled in this retrospective study. These above-mentioned patients were divided into two groups based on the Deauville criteria. Diagnostic efficiency of 18F-FDG PET/CT and integrated CT in detecting lymphoma were calculated. Consistencies were evaluated by comparing 18F-FDG PET/CT and integrated CT results through kappa coefficient. Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparisons. Prognostic factor analysis was performed by the Cox regression model. Results: The sensitivity, specificity, positive predictive value, negative predictive value, accuracy of post-SCT 18F-FDG PET-CT were 100%(12/12), 92.2%(47/51), 75.0%(12/16), 100%(47/47) and 93.7%(59/63). The consistency of 18F-FDG PET-CT and integrated CT was moderate(Kappa = .702，P < .001). Positive post-SCT 18F-FDG PET-CT was associated with lower progression-free survival (PFS) but not overall survival (OS) (p = .000 and p = .056, respectively). The 3-year PFS of the PET-positive group and PET-negative group was 18.8% and 70.2%, respectively. Multivariate analysis showed that post-SCT PET-CT findings was an independent prognostic factor for PFS (p = .000; HR, 3.957; 95%CI, 1.839-8.514). Other factors independently affecting PFS were sex (p = .018; HR, 2.588; 95% CI, 1.181 − 5.670) and lactate dehydrogenase (LDH) (p = .005; HR, 3.246; 95% CI, 1.419 − 7.426). However, none of the above-mentioned factors were associated with OS. Conclusions: Collectively, we found that 18F-FDG PET-CT after allo-SCT was a strong indicator for PFS, but not OS, which might provide important evidence for the selection of subsequent treatment regimen for LBL patients. Trial registration number: ChiCTR2100046709.

160 SURVIVAL ANALYSIS OF 18F-FDG PET/CT QUANTITATIVE PARAMETERS MEASURED IN PRIMARY TUMOR AND SUSPICIOUS LYMPH NODES IN PATIENTS WITH ESOPHAGEAL CARCINOMA

2020 ◽  
Vol 33 (Supplement_1) ◽  
Author(s):  
F Tustumi ◽  
F Takeda ◽  
P Duarte ◽  
D Albenda ◽  
R Sallum ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Burden Of Disease ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Trimodal Therapy ◽  
Pet Ct ◽  
Medicine Physician ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract   18F-FDG PET/CT quantitative techniques have been described as prognostic indicators in esophageal cancer. Objective: To evaluate the prognostic value of the maximal Standardized Uptake Value (SUVmax), the Metabolic Tumor Value (MTV) and the Total Lesion Glycolysis (TLG) measured in the primary tumor and in the suspicious lymph node. Methods A cohort study was performed to assess the association of SUVmax, MTV and TLG measured prior and post to neoadjuvant therapy, as well as the variation of these values between the two studies, with overall survival (OS) in patients with esophageal cancer submitted to trimodal therapy. The quantitative techniques were applied in the primary tumor (PT) and in the suspicious nodes (LN) by a nuclear medicine physician. The OS rates were analysed. Before neoadjuvant therapy, 106 patients had PET/CT, and 39 patients had post neoadjuvant PET/CT exams. Results Before neoadjuvant period all the variables related to LN were able to predict OS. MTV of primary (HR: 1.89; 95%CI: 1.01–3.52) tumor were also able to predict OS. On post neoadjuvant period and the variation pre-to-post neoadjuvant periods, none of the PET/CT variables related to LN were related to prognosis. All primary tumor volumetric variables were related to OS. MTV (HR: 4.66; 95%CI: 1.54–14.08) and TLG (HR: 4.86; 95%CI: 1.66–14.26) of PT of post neoadjuvant period; and the variation of MTV (HR: 2.95; 95%CI: 1.01–3.52) and TLG (HR: 3.49; 95%CI: 1.01–3.52) of the PT pre-to-post neoadjuvant periods were prognostic variables. Conclusion In patients with esophageal cancer, the burden of disease in the suspicious nodes and primary tumor prior to therapy and the residual burden of disease in PT in post therapy 18F-FDG PET/CT were associated with dismal prognosis.

scholarly journals Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer

2020 ◽  
Vol 26 (4) ◽  
pp. 2683-2691
Author(s):  
Zsuzsanna Nemeth ◽  
Wouter Wijker ◽  
Zsolt Lengyel ◽  
Erika Hitre ◽  
Katalin Borbely
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Metastatic Colorectal Cancer ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Metabolic Parameters ◽  
First Line ◽  
Pet Ct ◽  
Fdg Pet Ct

AbstractWe tested the prognostic relevance of metabolic parameters and their relative changes in patients with metastatic colorectal cancer (mCRC) treated with monoclonal antibody and chemotherapy. SUVmax (standardized uptake volume), SAM (standardized added metabolic activity) and TLG (total lesion glycolysis) are assessed with 18F-fluorodeoxyglucosepositron emission tomography and computed tomography (FDG-PET/CT) to evaluate total metabolic activity of malignant processes. Our purpose was to investigate the change of glucose metabolism in relation to PFS (progression free survival) and OS (overall survival). Fifty-three patients with mCRC with at least one measurable liver metastasis were included in this prospective, multi-center, early exploratory study. All patients were treated with first-line chemotherapy and targeted therapy. Metabolic parameters, like SUVmax, SAM, normalized SAM (NSAM) and TLG were assessed by FDG-PET/CT, carried out at baseline (scan-1) and after two therapeutic cycle (scan-2). Our results suggested neither SUVmax nor TLG have such prognostic value as NSAM in liver metastases of colorectal cancer. The parameters after the two cycles of chemotherapy proved to be better predictors of the clinical outcome. NSAM after two cycles of treatment has a statistically significant predictive value on OS, while SAM was predictive to the PFS. The follow up normalized SAM after 2 cycles of first line oncotherapy was demonstrated to be useful as prognostic biomarkers for OS in metastatic colorectal cancer. We should introduce this measurement in metastatic colorectal cancer if there is at least one metastasis in the liver.

Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET

2020 ◽  
Vol 129 ◽  
pp. 109076
Author(s):  
Dragana P. Sobic Saranovic ◽  
Marina Nikitovic ◽  
Jelena Saponjski ◽  
Isidora Grozdic Milojevic ◽  
Lejla Paripovic ◽  
...  
Keyword(s):  
Ewing Sarcoma ◽  
Fdg Pet ◽  
Young Patients ◽  
Progression Free Survival ◽  
Post Treatment ◽  
Free Survival ◽  
Pet Ct ◽  
Blue Cell ◽  
Fdg Pet Ct

scholarly journals Prognostic Value of Quantitative 18F-FDG PET/CT Parameters Measured in Primary Tumors and Suspicious Lymph Nodes in Patients With Esophageal Carcinoma

2020 ◽  
Author(s):  
Francisco Tustumi ◽  
Flávio Roberto Takeda ◽  
Paulo Schiavom Duarte ◽  
David Gutiérrez Albenda ◽  
Rubens Antonio Aissar Sallum ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Neoadjuvant Therapy ◽  
Burden Of Disease ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Primary Tumors ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Objective:Quantitative 18F-FDG PET/CT parameters have been described as prognostic indicators in esophageal cancer. The objective of this study isto evaluate the prognostic value of the maximum standardized uptake value (SUVmax), metabolic tumor value (MTV) and total lesion glycolysis (TLG) measured in the primary tumor and suspicious lymph nodes.Methods: A cohort study was performed to assess the association of SUVmax, MTV and TLG measured prior to and post neoadjuvant therapywithoverall survival (OS) of patients with esophageal cancer who received trimodal therapy. The quantitative techniques were applied in the primary tumor and suspicious lymph nodes. The OS rates were analyzed. Results: Before neoadjuvant therapy, 106 patients underwent PET/CT, and 39 patients underwent post-neoadjuvant therapy PET/CT exams. Before neoadjuvanttherapy, PET/CT showed that all the variables of the evaluated lymph nodes were statistically significant in predicting OS. Postneoadjuvanttherapy, none of the PET/CT variables of lymph nodes were related to prognosis. On the other hand, all primary tumor volumetric variables were related to overall survival. The MTV (HR: 4.66; 95% CI: 1.54-14.08) and TLG (HR: 4.86; 95% CI: 1.66-14.26) of the primary tumor post neoadjuvanttherapy and the variations in MTV (HR: 2.95; 95% CI: 1.01-3.52) and TLG (HR: 3.49; 95% CI: 1.01-3.52) of the primary tumor pre-to-post-neoadjuvanttherapy were prognostic variables. Conclusion: In patients with esophageal cancer, the burden of disease in suspicious lymph nodes and the primary tumor prior to therapy and the residual burden of disease in the primary tumor post therapy assessed by PET/CT were associated with prognosis.

Sign in / Sign up

Export Citation Format

Share Document